At ASCO 2021 much of the attention in the field of lung cancer went to early-stage non-small cell lung cancer (NSCLC) discussing both (neo)adjuvant strategies and local treatment modalities. In metastatic NSCLC, we would like to highlight some recent (chemo)immunotherapeutic advances in the treatment of non-oncogene addicted tumours as well as promising strategies to overcome osimertinib resistance, targeting of KRAS G12C mutated tumours and updated results for EGFR exon 20, HER2 exon 20, MET and RET targeting. As a final abstract, the results of the randomised phase III CALGB 30610/RTOG 0538 trial evaluating high-dose thoracic radiotherapy in small cell lung cancer will be summarised. We would like to acknowledge Prof. Veerle Surmont (University Hospital Ghent) for her help in selecting the abstracts discussed in this overview.
